OAK: Impact of Continued Atezolizumab Beyond PD in Pts With Advanced NSCLC

June 2-6, 2017; Chicago, Illinois

Patients who remained on atezolizumab after progression of disease by RECIST continued to derive benefit.

Format: Microsoft PowerPoint (.ppt)

File Size: 525 KB

Released: June 7, 2017

Acknowledgements

Supported by educational grants by

AbbVie
Amgen
AstraZeneca
Celgene Corporation
Genentech
Halozyme Therapeutics
Incyte
Merck & Co., Inc.

Cookie Settings